NEW YORK (GenomeWeb) – A Duke University team has found early evidence that breast cancer cases marked by PIK3CA mutations may be vulnerable to combined treatments targeting programmed cell death and mTOR signaling pathways.
NEW YORK (GenomeWeb) – A Duke University team has found early evidence that breast cancer cases marked by PIK3CA mutations may be vulnerable to combined treatments targeting programmed cell death and mTOR signaling pathways.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.